Subtotal $0.00
Shop Now
The Wegovy pill is a once-daily semaglutide tablet made by Novo Nordisk. The FDA approved it on December 22, 2025, for long-term weight management in adults with obesity, or with overweight plus a weight-related health condition, and to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight. It is the first oral GLP-1 medicine approved for weight management in the United States, and it reached U.S. pharmacies on January 5, 2026. This guide covers what the label says, what the OASIS 4 trial found, how the pill differs from Rybelsus and the Wegovy injection, and its safety information.
Peptide Labs does not sell the Wegovy pill or any prescription drug. This article is general information, not medical advice. The Wegovy pill is prescription-only, and whether it suits a given person is a decision for a licensed healthcare provider.
Key Takeaways
- The Wegovy pill is oral semaglutide, the same active ingredient as the Wegovy injection, Ozempic and Rybelsus.
- FDA approval came on December 22, 2025, for weight management and cardiovascular risk reduction in adults.
- In the OASIS 4 trial, average weight loss was 13.6% at 64 weeks, versus 2.2% on placebo.
- The label has specific instructions about taking it each morning on an empty stomach.
- It carries the same boxed warning about thyroid C-cell tumors as other semaglutide products.
What is the Wegovy pill?
The Wegovy pill is semaglutide in tablet form. Semaglutide is a GLP-1 receptor agonist, a peptide drug that mimics glucagon-like peptide-1, a gut hormone involved in appetite, fullness, stomach emptying and blood sugar control. Until the pill arrived, Wegovy was only available as a once-weekly injection. Both forms now share one U.S. prescribing information document, which was most recently revised in June 2026.
Because only a small share of a peptide swallowed as a tablet is absorbed, the pill contains far more semaglutide than a weekly injection. It comes in four strengths, 1.5, 4, 9 and 25 mg. Treatment starts at the lowest strength and a prescriber steps it up at monthly intervals to the 25 mg maintenance tablet, which is the strength studied in the main trial. For background on the molecule itself, see our semaglutide profile.
What the FDA approved
According to the label, Wegovy tablets are approved for use with a reduced-calorie diet and increased physical activity for two purposes:
- Weight management: to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight and at least one weight-related condition.
- Cardiovascular risk: to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
The tablet’s approval is narrower than the injection’s. Wegovy injection is also approved for adolescents aged 12 and older with obesity and, under accelerated approval, for a form of fatty liver disease called MASH with moderate to advanced fibrosis. The label states that the safety of the tablets has not been established in children or in patients with MASH. It also says Wegovy should not be combined with other semaglutide products or any other GLP-1 receptor agonist.
OASIS 4: what the main trial found
The approval rested mainly on OASIS 4, published in the New England Journal of Medicine in September 2025. The trial enrolled 307 adults without diabetes who had obesity, or overweight with at least one weight-related condition. They were randomly assigned, two to one, to oral semaglutide 25 mg or placebo once daily, alongside diet and activity counseling, for 64 weeks of treatment followed by 7 weeks off the drug.
- Average weight change at 64 weeks was -13.6% with the pill and -2.2% with placebo in the published paper. The label’s own analysis of the same trial lists -13.6% versus -2.4%.
- According to the label, 27.9% of people on the pill lost 20% or more of their body weight, compared with 3.1% on placebo.
- Novo Nordisk has also cited an average of 16.6%, a figure that estimates the result if everyone had kept taking the pill as directed.
- Digestive side effects were reported by 74.0% of the semaglutide group and 42.2% of the placebo group.
The trial has limits worth knowing. It was modest in size, 79% of participants were women and 92% were White, people with type 2 diabetes were excluded, and it was funded by Novo Nordisk. The results are group averages, and individual responses varied widely.
Wegovy pill vs Rybelsus vs Wegovy injection
All three products contain semaglutide, but they are approved for different uses, come in different strengths and are not interchangeable.
| Wegovy pill | Rybelsus | Wegovy injection | |
|---|---|---|---|
| Form | Daily tablet | Daily tablet | Weekly injection |
| Main approved use | Weight management; cardiovascular risk reduction | Blood sugar control in type 2 diabetes; cardiovascular risk reduction in type 2 diabetes | Weight management; cardiovascular risk reduction; MASH with fibrosis |
| Approved ages | Adults | Adults | Adults, and ages 12+ for weight management |
| Strengths | 1.5, 4, 9 and 25 mg | 3, 7 and 14 mg | Pens from 0.25 mg up to 7.2 mg (Wegovy HD) |
| Empty-stomach rules | Yes | Yes | No; any time of day, with or without meals |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors | Thyroid C-cell tumors |
Rybelsus has been sold since 2019 for type 2 diabetes. Its current label, revised in January 2026, also covers a newer tablet formulation sold as Ozempic tablets, and it states that the two are not substitutable milligram for milligram. The Wegovy label describes how a prescriber can switch someone between the Wegovy injection and the pill, but that is a clinical decision, not something to do on your own. For how semaglutide compares with tirzepatide, read semaglutide vs tirzepatide.
How it is taken: the label's empty-stomach rules
Oral semaglutide is absorbed poorly when there is food or much liquid in the stomach, so the label has specific instructions about taking it on an empty stomach. In general terms, the tablet is taken once a day in the morning, before eating, with only a limited amount of plain water, and swallowed whole rather than split, crushed or chewed. The label then asks patients to wait a set time before eating, drinking anything else or taking other oral medicines. The Medication Guide and the pharmacist spell out the exact instructions, including what to do about a missed tablet.
Because semaglutide slows stomach emptying, it can also affect how other oral medicines are absorbed. The label advises closer monitoring for medicines that need precise blood levels, so anyone taking the pill should give their prescriber and pharmacist a full medication list.
Wegovy pill side effects and boxed warning
The label carries a boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it is not known whether it causes them, including medullary thyroid carcinoma, in humans. Wegovy is not for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
The label says the types and frequency of common side effects with the tablet were similar to those seen with the injection: mainly nausea, diarrhea, vomiting, constipation and stomach pain, most often while the dose is being increased. Label figures specific to the tablet include:
- 6.9% of people on the tablet and 5.9% on placebo stopped because of side effects.
- Severe digestive side effects occurred in 2% on the tablet and 0% on placebo.
- Altered skin sensations (dysesthesia) were reported by 5% on the tablet and none on placebo.
- Gallstones were reported by 2.5% on the tablet and 1% on placebo.
Other warnings on the label cover pancreatitis, gallbladder disease, low blood sugar when combined with insulin or a sulfonylurea, kidney injury linked to dehydration, serious allergic reactions, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, and the risk of inhaling stomach contents during anesthesia or deep sedation. Wegovy should be stopped when pregnancy is recognized, and the label says breastfeeding is not recommended while taking the tablets. In January 2026 the FDA had a warning about suicidal thoughts removed from Wegovy’s label after its review found no increased risk. Our full guide to semaglutide side effects covers each warning.
Availability and launch
Novo Nordisk launched the Wegovy pill in the United States on January 5, 2026. The starting strength was available that day through retail pharmacies and select telehealth providers, and the company said the higher strengths would follow by the end of that week. A prescription is required. Tablets or powders sold online as “oral semaglutide” without a prescription are not the approved product, and the FDA has warned about unapproved and counterfeit semaglutide.
Other oral options
The Wegovy pill is not the only daily tablet for weight management. In April 2026 the FDA approved Eli Lilly’s orforglipron, sold as Foundayo, a small-molecule GLP-1 drug with no food or water restrictions on its label. No trial has compared the two pills directly at their weight-management strengths. For an overview of every approved and investigational option, see our guide to peptides for weight loss.
Frequently Asked Questions
When was the Wegovy pill approved?
The FDA approved Wegovy tablets on December 22, 2025, for weight management and cardiovascular risk reduction in certain adults. Novo Nordisk launched the pill in the United States on January 5, 2026.
Is the Wegovy pill the same as Rybelsus?
No. Both contain semaglutide, but Rybelsus is approved for adults with type 2 diabetes and comes in lower strengths, while the Wegovy pill is approved for weight management and cardiovascular risk reduction. They are not interchangeable.
How much weight did people lose on the Wegovy pill?
In the OASIS 4 trial, adults without diabetes lost an average of 13.6% of their body weight over 64 weeks, compared with 2.2% on placebo. Results varied widely between individuals.
Is the Wegovy pill as effective as the injection?
No head-to-head trial has compared them. OASIS 4 results were broadly similar to earlier results with the injection, but comparisons across separate trials are unreliable.
What are the side effects of the Wegovy pill?
The most common are digestive: nausea, diarrhea, vomiting, constipation and stomach pain, mostly while the dose is increased. The label also includes a boxed warning about thyroid C-cell tumors and warnings about pancreatitis, gallbladder disease and kidney problems from dehydration.
Why does the Wegovy pill have to be taken on an empty stomach?
Food and other drinks sharply reduce how much oral semaglutide is absorbed. The label has specific instructions about timing, water and waiting before eating, which a pharmacist can explain.
Can I buy the Wegovy pill without a prescription?
No. It is a prescription-only drug in the United States. Peptide Labs does not sell it or any other prescription medicine.
This article is general information, not medical advice. Peptide Labs does not sell prescription drugs, including any product named here. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed September 2026.
Related guides: Ozempic Pill: Ozempic Tablets, Rybelsus and the Wegovy Pill Explained, Wegovy Side Effects: Injection, Pill, Teens and Wegovy HD, Foundayo (Orforglipron): Lilly’s GLP-1 Pill Explained, How Long Does Ozempic Take to Work? Labels and Trials Explained.